{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:43Z","timestamp":1790882383065,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40272-023-00580-z","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T12:02:11Z","timestamp":1689595331000},"page":"557-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A Review of Histamine-2 Receptor Antagonist and Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease in Neonates and Infants"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-2876","authenticated-orcid":false,"given":"Jason","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Jeffries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6801-1249","authenticated-orcid":false,"given":"Roxane","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"580_CR1","first-page":"705","volume":"92","author":"DC Baird","year":"2015","unstructured":"Baird DC, Harker DJ, Karmes AS. Diagnosis and treatment of gastroesophageal reflux in infants and children. Am Fam Physician. 2015;92:705\u201314.","journal-title":"Am Fam Physician"},{"key":"580_CR2","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1542\/neo.17-4-e203","volume":"17","author":"DR Duncan","year":"2016","unstructured":"Duncan DR, Rosen RL. Current insights into pharmacologic and nonpharmacologic management of gastroesophageal reflux in infants. NeoReviews. 2016;17:e203\u201312. https:\/\/doi.org\/10.1542\/neo.17-4-e203.","journal-title":"NeoReviews"},{"key":"580_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-1061","volume":"142","author":"EC Eichenwald","year":"2018","unstructured":"Eichenwald EC, AAP Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants. Pediatrics. 2018;142: e20181061. https:\/\/doi.org\/10.1542\/peds.2018-1061.","journal-title":"Pediatrics"},{"key":"580_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MPG.0000000000001889","volume":"66","author":"R Rosen","year":"2018","unstructured":"Rosen R, Vandenplas Y, Singendonk M, Cabana M, DiLorenzo C, Gottrand F, et al. Pediatric gastroesophageal reflux clinical practice guidelines: Joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:516\u201354. https:\/\/doi.org\/10.1097\/MPG.0000000000001889.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jpeds.2013.05.007","volume":"163","author":"G Davidson","year":"2013","unstructured":"Davidson G, Wenzl TG, Thomson M, Omari T, Barker P, Lundborg P, et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr. 2013;163:692\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2013.05.007.","journal-title":"J Pediatr"},{"key":"580_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10620-010-1321-3","volume":"56","author":"J Kierkus","year":"2011","unstructured":"Kierkus J, Furmaga-Jablonska W, Sullivan JE, David ES, Stewart DL, Rath N, et al. Pharmacodynamics and safety of pantoprazole in neonates, preterm infants and infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease. Dig Dis Sci. 2011;56:425\u201334. https:\/\/doi.org\/10.1007\/s10620-010-1321-3.","journal-title":"Dig Dis Sci"},{"key":"580_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166207","volume":"11","author":"F Kaguelidou","year":"2016","unstructured":"Kaguelidou F, Alberti C, Biran V, Bourdon O, Farnoux C, Zohar S, et al. Dose-finding study of omeprazole on gastric pH in neonates with gastro-esophageal acid reflux using a Bayesian sequential approach. PLoS ONE. 2016;11: e0166207. https:\/\/doi.org\/10.1371\/journal.pone.0166207.","journal-title":"PLoS ONE"},{"key":"580_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.mpg.0000252190.97545.07","volume":"44","author":"TI Omari","year":"2007","unstructured":"Omari TI, Haslam RR, Lundborg P, Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007;44:41\u20134. https:\/\/doi.org\/10.1097\/01.mpg.0000252190.97545.07.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jpeds.2009.02.025","volume":"155","author":"T Omari","year":"2009","unstructured":"Omari T, Lundborg P, Sandstrom M, Bondarov P, Fjellman M, Haslam R, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr. 2009;155:222\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2009.02.025.","journal-title":"J Pediatr"},{"key":"580_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2165\/00148581-200810040-00004","volume":"10","author":"M Springer","year":"2008","unstructured":"Springer M, Atkinson S, North J, Raanan M. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged < 1 year. Pediatr Drugs. 2008;10:255\u201363. https:\/\/doi.org\/10.2165\/00148581-200810040-00004.","journal-title":"Pediatr Drugs"},{"key":"580_CR11","first-page":"284","volume":"67","author":"SY Tham","year":"2012","unstructured":"Tham SY, Rogers IM, Samuel KF, Singh A, Ong KK. Dose oral lansoprazole really reduce gastric acidity in VLBW premature neonates? Med J Malaysia. 2012;67:284\u20138.","journal-title":"Med J Malaysia"},{"key":"580_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00228-010-0811-8","volume":"66","author":"RM Ward","year":"2010","unstructured":"Ward RM, Tammara B, Sullivan SE, Stewart DL, Rath N, Meng X, et al. Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). Eur J Clin Pharmacol. 2010;66:555\u201361. https:\/\/doi.org\/10.1007\/s00228-010-0811-8.","journal-title":"Eur J Clin Pharmacol"},{"key":"580_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jpeds.2009.03.044","volume":"155","author":"E Wheatley","year":"2009","unstructured":"Wheatley E, Kennedy KA. Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants. J Pediatr. 2009;155:516\u201321. https:\/\/doi.org\/10.1016\/j.jpeds.2009.03.044.","journal-title":"J Pediatr"},{"key":"580_CR14","unstructured":"Ranitidine. In: Micromedex [database on the Internet]. Greenwood Village (CO): IBM Corporation; 2023 [cited 2023 Jan 27]. Available from www.micromedexsolutions.com. Subscription required to view."},{"key":"580_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1067\/S0022-3476(03)00207-5","volume":"143","author":"DJ Moore","year":"2003","unstructured":"Moore DJ, Tao BSK, Lines DR, Hirte C, Heddle ML, Davidson GP. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143:219\u201323. https:\/\/doi.org\/10.1067\/S0022-3476(03)00207-5.","journal-title":"J Pediatr"},{"key":"580_CR16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/01.mpg.0000469415.50085.f7","volume":"45","author":"T Omari","year":"2007","unstructured":"Omari T, Davidson G, Bondarov P, Naucl\u00e9r E, Nilsson C, Lundborg P. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1\u201324 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:530\u20137. https:\/\/doi.org\/10.1097\/01.mpg.0000469415.50085.f7.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s13318-020-00630-8","volume":"45","author":"P Bestebreurtje","year":"2020","unstructured":"Bestebreurtje P, de Koning BAE, Roeleveld N, Knibbe CAJ, Tibboel D, van Groen B, et al. Rectal omeprazole in infants with gastroesophageal reflux disease: a randomized pilot trial. Eur J Drug Metab Pharmacokinet. 2020;45:635\u201343. https:\/\/doi.org\/10.1007\/s13318-020-00630-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"580_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/MPG.0000000000000195","volume":"58","author":"S Hussain","year":"2014","unstructured":"Hussain S, Kierkus J, Hu P, Hoffman D, Lekich R, Sloan S, et al. Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2014;58:226\u201336. https:\/\/doi.org\/10.1097\/MPG.0000000000000195.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jpeds.2008.09.054","volume":"154","author":"SR Orenstein","year":"2009","unstructured":"Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety or proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154:514\u201320. https:\/\/doi.org\/10.1016\/j.jpeds.2008.09.054.","journal-title":"J Pediatr"},{"key":"580_CR20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.1365-2036.2003.01559.x","volume":"17","author":"SR Orenstein","year":"2003","unstructured":"Orenstein SR, Shalaby TM, Devandry SN, Liacouras CA, Czinn SJ, Dice JE, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 2003;17:1097\u2013107. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01559.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"580_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/MPG.0b013e3181c2bf41","volume":"50","author":"H Winter","year":"2010","unstructured":"Winter H, Kum-Nji P, Mahomedy SH, Kierkus J, Hinz M, Li H, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1\u201311 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2010;50:609\u201318. https:\/\/doi.org\/10.1097\/MPG.0b013e3181c2bf41.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0B013E3182496B35","author":"H Winter","year":"2015","unstructured":"Winter H, Gunasekaran T, Tolia V, Gottrand F, Barker PN, Illueca M. Esomeprazole for the treatment of GERD in infants ages 1\u201311 months. J Pediatr Gastroenterol Nutr. 2015. https:\/\/doi.org\/10.1097\/MPG.0B013E3182496B35.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MPG.0b013e31815667d7","volume":"46","author":"V Khoshoo","year":"2008","unstructured":"Khoshoo V, Dhume P. Clinical response to 2 dosing regiments of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 2008;46:352\u20134. https:\/\/doi.org\/10.1097\/MPG.0b013e31815667d7.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.0315","volume":"172","author":"E Mitre","year":"2018","unstructured":"Mitre E, Susi A, Kropp LE, Schwartz DJ, Gorman GH, Nylund CM. Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA Pediatr. 2018;172: e180315. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.0315.","journal-title":"JAMA Pediatr"},{"key":"580_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1515\/jpm-2016-0285","volume":"45","author":"UP Patil","year":"2017","unstructured":"Patil UP, Bailey SM, Wachtel EV, Orosz E, Zarchin R, Mally PV. Efficacy of and potential morbidities associate with the use of antacid medications in preterm neonates. J Perinat Med. 2017;45:947\u201352. https:\/\/doi.org\/10.1515\/jpm-2016-0285.","journal-title":"J Perinat Med"},{"key":"580_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9649162","author":"N Singh","year":"2016","unstructured":"Singh N, Dhayade A, Mohamed AL, Chaudhari TV. Morbidiy and mortality in preterm infants following antacid use: a retrospective audit. Int J Pediatr. 2016. https:\/\/doi.org\/10.1155\/2016\/9649162.","journal-title":"Int J Pediatr"},{"key":"580_CR27","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1542\/peds.2005-1543","volume":"117","author":"R Guillet","year":"2006","unstructured":"Guillet R, Stoll BJ, Cotton CM, Gantz M, McDonald S, Poole WK, Phelps DL. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006;117:e137\u201342. https:\/\/doi.org\/10.1542\/peds.2005-1543.","journal-title":"Pediatrics"},{"key":"580_CR28","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1542\/peds.2011-0796","volume":"129","author":"G Terrin","year":"2012","unstructured":"Terrin G, Passariello A, De Curtis M, Manguso F, Salvia G, Lega L, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012;129:e40\u20135. https:\/\/doi.org\/10.1542\/peds.2011-0796.","journal-title":"Pediatrics"},{"key":"580_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1515\/JPM.2007.017","volume":"35","author":"S Bianconi","year":"2007","unstructured":"Bianconi S, Gudavalli M, Sutija VG, Lopez AL, Barillas-Arias L, Ron N. Ranitidine and late-onset sepsis in the neonatal intensive care unit. J Perinat Med. 2007;35:147\u201350. https:\/\/doi.org\/10.1515\/JPM.2007.017.","journal-title":"J Perinat Med"},{"key":"580_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pedneo.2013.01.011","volume":"54","author":"A Bilali","year":"2013","unstructured":"Bilali A, Galanis P, Bartsocas C, Sparos L, Velonakis E. H2-blocker therapy and incidence of necrotizing enterocolitis in preterm infants: a case-control study. Pediatr Neonatol. 2013;54:141\u20132. https:\/\/doi.org\/10.1016\/j.pedneo.2013.01.011.","journal-title":"Pediatr Neonatol"},{"key":"580_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.earlhumdev.2016.05.010","volume":"99","author":"A Romaine","year":"2016","unstructured":"Romaine A, Ye D, Ao Z, Fang F, Johnson O, Blake T, et al. Safety of histamine-2 receptor blockers in hospitalized VLBW infants. Early Hum Dev. 2016;99:27\u201330. https:\/\/doi.org\/10.1016\/j.earlhumdev.2016.05.010.","journal-title":"Early Hum Dev"},{"key":"580_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12879-017-2482-x","volume":"17","author":"RNS Santana","year":"2017","unstructured":"Santana RNS, Santos VS, Riberio-J\u00fanior RF, Freire MS, Menezes MAS, Cipolotti R, et al. Use of ranitidine is associated with infections in newborns hospitalized in a neonatal intensive care unit: a cohort study. BMC Infect Dis. 2017;17:375. https:\/\/doi.org\/10.1186\/s12879-017-2482-x.","journal-title":"BMC Infect Dis"},{"key":"580_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jpeds.2016.03.059","volume":"174","author":"JL Slaughter","year":"2017","unstructured":"Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Neonatal h2-receptor antagonist and proton pump inhibitor treatment at US children\u2019s hospitals. J Pediatr. 2017;174:63-70.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2016.03.059.","journal-title":"J Pediatr"},{"key":"580_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13278","volume":"30","author":"F Cresi","year":"2018","unstructured":"Cresi F, Martinelli D, Maggiora E, Locatelli E, Liguori SA, Baldassarre ME, et al. Cardiorespiratory events in infants with gastroesophageal reflux symptoms: is there any association? Neurogastroenterol Motil. 2018;30: e13278. https:\/\/doi.org\/10.1111\/nmo.13278.","journal-title":"Neurogastroenterol Motil"},{"key":"580_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.earlhumdev.2019.05.003","volume":"134","author":"S Nobile","year":"2019","unstructured":"Nobile S, Marchionni P, Noviello C, Carnielli VP. Correlation between cardiorespiratory events and gastro-esophageal reflux in preterm and term infants: analysis of predisposing factors. Early Hum Dev. 2019;134:14\u20138. https:\/\/doi.org\/10.1016\/j.earlhumdev.2019.05.003.","journal-title":"Early Hum Dev"},{"key":"580_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/jp.2010.27","volume":"30","author":"J Di Fiore","year":"2010","unstructured":"Di Fiore J, Arko M, Herynk B, Martin R, Hibbs AM. Charcterization of cardiorespiratory events following gastroesophageal reflux (GER) in preterm infants. J Perinatol. 2010;30:683\u20137. https:\/\/doi.org\/10.1038\/jp.2010.27.","journal-title":"J Perinatol"},{"key":"580_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41390-020-0932-4","volume":"89","author":"SR Jadcherla","year":"2021","unstructured":"Jadcherla SR, Hasenstab KA, Wei L, Osborn EK, Viswanathan S, Gulati IK, et al. Role of feeding strategy bundle with acid-suppressive therapy in infants with esophageal acid reflux exposure: a randomized controlled trial. Pediatr Res. 2021;89:645\u201352. https:\/\/doi.org\/10.1038\/s41390-020-0932-4.","journal-title":"Pediatr Res"},{"key":"580_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00003088-200544050-00001","volume":"44","author":"C Litalien","year":"2005","unstructured":"Litalien C, Th\u00e9or\u00e9t Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44:441\u201366. https:\/\/doi.org\/10.2165\/00003088-200544050-00001.","journal-title":"Clin Pharmacokinet"},{"key":"580_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","volume":"15","author":"RM Ward","year":"2013","unstructured":"Ward RM, Kearns GL. Proton pump inhibitors in pediatrics mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Pediatr Drugs. 2013;15:119\u201331. https:\/\/doi.org\/10.1007\/s40272-013-0012-x.","journal-title":"Pediatr Drugs"},{"key":"580_CR40","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1572-0241.2006.00442.x","volume":"101","author":"SR Orenstein","year":"2006","unstructured":"Orenstein SR, Shalaby TM, Kelsey SF, Frankel E. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol. 2006;101:628\u201340. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00442.x.","journal-title":"Am J Gastroenterol"},{"key":"580_CR41","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.1002\/14651858.CD011785.pub2","volume":"7","author":"DS Green","year":"2019","unstructured":"Green DS, Abdel-Latif ME, Jones LJ, Lui K, Osborn DA. Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants. Cochrane Database Syst Rev. 2019;7:11785. https:\/\/doi.org\/10.1002\/14651858.CD011785.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"580_CR42","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1111\/j.1365-2982.2011.01763.x","volume":"23","author":"N Rommel","year":"2011","unstructured":"Rommel N, van Wijk M, Boets B, Hebbard G, Haslam R, Davidson G, et al. Development of pharyngo-esophageal physiology during swallowing in the preterm infant. Neurogastroenterol Motil. 2011;23:e401\u20138. https:\/\/doi.org\/10.1111\/j.1365-2982.2011.01763.x.","journal-title":"Neurogastroenterol Motil"},{"key":"580_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.5223\/pghn.2019.22.2.107","volume":"22","author":"JIG Ayerbe","year":"2019","unstructured":"Ayerbe JIG, Hauser B, Salvatore S, Vandenplas Y. Diagnosis and management of gastroesophageal reflux disease in infants and children: from guidelines to clinical practice. Pediatr Gastroenterol Hepatol Nutr. 2019;22:107\u201321. https:\/\/doi.org\/10.5223\/pghn.2019.22.2.107.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"580_CR44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/bcp.12619","volume":"80","author":"S Cohen","year":"2015","unstructured":"Cohen S, de Mesquita MB, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015;80:200\u20138. https:\/\/doi.org\/10.1111\/bcp.12619.","journal-title":"Br J Clin Pharmacol"},{"key":"580_CR45","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.21037\/atm-20-2284","volume":"8","author":"Y Li","year":"2020","unstructured":"Li Y, Xiong M, Yang M, Wang L, Nie S, Liu D, et al. Proton pump inhibitors and the risk of hospital-acquired acute kidney injury in children. Ann Transl Med. 2020;8:1438. https:\/\/doi.org\/10.21037\/atm-20-2284.","journal-title":"Ann Transl Med."},{"key":"580_CR46","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1017\/ice.2019.23","volume":"40","author":"S Anjewierden","year":"2019","unstructured":"Anjewierden S, Han Z, Foster CB, Pant C, Deshpande A. Risk factors for Clostridium difficile infection in pediatric inpatients: a meta-analysis and systematic review. Infect Control Hosp Epidemiol. 2019;40:420\u20136. https:\/\/doi.org\/10.1017\/ice.2019.23.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"580_CR47","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jmii.2018.09.002","volume":"53","author":"TH Chang","year":"2020","unstructured":"Chang TH, Hsu WY, Yang TI, Lu CY, Hsueh PR, Chen JM, et al. Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children. J Microbiol Immunol Infect. 2020;53:578\u201384. https:\/\/doi.org\/10.1016\/j.jmii.2018.09.002.","journal-title":"J Microbiol Immunol Infect"},{"key":"580_CR48","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0857","volume":"144","author":"CJ Bernal","year":"2019","unstructured":"Bernal CJ, Aka I, Carroll RJ, Coco JR, Lima JJ, Acra SA, et al. CYP2C19 phenotype and risk of proton pump inhibitor-associated infections. Pediatrics. 2019;144: e20190857. https:\/\/doi.org\/10.1542\/peds.2019-0857.","journal-title":"Pediatrics"},{"key":"580_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.5527\/wjn.v5.i2.152","volume":"5","author":"JH William","year":"2016","unstructured":"William JH, Danziger J. Proton-pump inhibitor-induced hypomagnesemia: current research and proposed mechanisms. World J Nephrol. 2016;5:152\u20137. https:\/\/doi.org\/10.5527\/wjn.v5.i2.152.","journal-title":"World J Nephrol."},{"key":"580_CR50","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/jamapediatrics.2020.5710","volume":"175","author":"YH Wang","year":"2021","unstructured":"Wang YH, Wintzell V, Ludvigsson JF, Svanstr\u00f6m H, Pasternak B. Association between proton pump inhibitor use and risk of asthma in children. JAMA Pediatr. 2021;175:394\u2013403. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.5710.","journal-title":"JAMA Pediatr"},{"key":"580_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapediatrics.2020.0007","volume":"174","author":"YH Wang","year":"2020","unstructured":"Wang YH, Wintzwell V, Ludvigsson JF, Svanstr\u00f6m H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatr. 2020;174:1\u201310. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.0007.","journal-title":"JAMA Pediatr"},{"key":"580_CR52","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-2625","volume":"144","author":"L Malchodi","year":"2019","unstructured":"Malchodi L, Wagner K, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. Pediatrics. 2019;144: e20182625. https:\/\/doi.org\/10.1542\/peds.2018-2625.","journal-title":"Pediatrics"},{"key":"580_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/jrms.JRMS_637_18","volume":"25","author":"F Famouri","year":"2020","unstructured":"Famouri F, Derakhshani F, Madihi Y, Shahsanai A. Electrolyte disturbances in children receiving omeprazole for gastroesophageal reflux disease. J Res Med Sci. 2020;25:106. https:\/\/doi.org\/10.4103\/jrms.JRMS_637_18.","journal-title":"J Res Med Sci"},{"key":"580_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000444210","volume":"110","author":"KG Snoek","year":"2016","unstructured":"Snoek KG, Reiss IKM, Greenough A, Capolupo I, Urlesberger B, Wessel L, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: The CDH EURO consortium consensus\u20142015 update. Neonatology. 2016;110:66\u201374. https:\/\/doi.org\/10.1159\/000444210.","journal-title":"Neonatology"},{"key":"580_CR55","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/MPG.0000000000001401","volume":"63","author":"U Krishnan","year":"2016","unstructured":"Krishnan U, Mousa H, Dall\u2019Oglio L, Homaira N, Rosen R, Faure C, et al. ESPGHAN-NASPGHAN guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with esophageal atresia-tracheoesophageal fistula. J Pediatr Gastroenterol Nutr. 2016;63:550\u201370. https:\/\/doi.org\/10.1097\/MPG.0000000000001401.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"580_CR56","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1542\/neo.22-2-e104","volume":"22","author":"JB Sanchez","year":"2021","unstructured":"Sanchez JB, Jadcherla SR. Gastroesophageal reflux disease in neonates: facts and figures. NeoReviews. 2021;22:e104\u201317. https:\/\/doi.org\/10.1542\/neo.22-2-e104.","journal-title":"NeoReviews"},{"key":"580_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/pch\/pxac068","volume":"27","author":"I Chevalier","year":"2022","unstructured":"Chevalier I, Beck CE, Dor\u00e9-Bergeron MJ, Orkin J. Medical management of gastro-esophageal reflux in healthy infants. Paediatr Child Health. 2022;27:503\u201311. https:\/\/doi.org\/10.1093\/pch\/pxac068.","journal-title":"Paediatr Child Health"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00580-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T08:44:20Z","timestamp":1691657060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00580-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00580-z","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"18 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"There are no conflicts of interest for Jason Tan, Sonia Jeffries, or Roxane Carr.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This manuscript has no associated data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors made substantial contributions to the conception and design of the work, and the acquisition, analysis, and interpretation of the data. All authors were involved in drafting the work and revising it critically for important intellectual content. All authors reviewed and provided approval for the final version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}}]}}